Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Von Hippel-Lindau Market by Tumor Site (Brain, Spine, Eyes, Kidneys, Adrenal Glands, Pancreas, Liver, Lungs, Inner Ears, Reproductive Tract), by Diagnosis (MRI Scan, CT Scan, Others) and by End User (Hospitals, Clinics, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A12687

Pages: NA

Charts: NA

Tables: NA

Von hippel-lindau is an autosomal disorder that can produce malignant tumors because of the mutation in the von hippel-lindau gene. It is one of the risk factors that can cause cancer. It is transmitted genetically in both females and males equally. A patient who underwent von hippel-lindau disease may also undergo cysts and tumors. Tumor can occur in ten distinct parts of the body which involve the eyes, brain, liver, kidney, inner ears, reproductive tract, pancreas, spine, lung, and adrenal glands. Even in the same family, the disease is different in every patient. Hence it is very challenging to predict when and how the von hippel-lindau disease will present in the individual.

COVID-19 Impact analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the von hippel-lindau market.

Top Impacting Factors

  • Increase in need for superior therapies, rise in awareness regarding cancer, and surge in number of tumor surgeries are factors that drive the growth of the von hippel-lindau market.
  • In addition, increase in healthcare expenditure for cancer research; rapid progress in molecular diagnostics, availability of skilled professionals; rise in R&D activities to facilitate drug development; are some factors, which boost the market growth for von hippel-lindau.
  • However, the extended clinical trial duration for future drugs and the non-availability of existing drug candidates to treat the syndrome may hinder the von hippel-lindau market growth.

Von Hippel-Lindau Market Trends

New product launches to flourish the market

The pharmaceutical giants are engaged in research and development to provide an advanced diagnosis.

Cellectar Biosciences Inc. is currently working on its CLR 131 small-molecule pyruvate dehydrogenase complex (PDC) to render targeted delivery of iodine-131 direct to cancer cells while restricting exposure to healthy cells. This candidate is meant to cure several types of pediatric cancers and is anticipated to address patients inheriting the von hippel-lindau gene in the future.

Key Benefits of the Report

  • This study presents the analytical depiction of the von hippel-lindau industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the von hippel-lindau market share.
  • The current market is quantitatively analyzed to highlight the von hippel-lindau market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the von hippel-lindau market.
  • The report provides a detailed von hippel-lindau market analysis based on competitive intensity and how the competition will take shape in coming years

Questions answered in the von hippel-lindau Report

  • Which are the leading players active in the von hippel-lindau market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the von hippel-lindau market?
  • What future projections would help in taking further strategic steps?
  • What is "Von hippel-lindau"?
  • What is "Von hippel-lindau" Market prediction in the future?
  • Who are the leading global players in the "Von hippel-lindau" Market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "Von hippel-lindau" Market report? 

 Key Market Segments

  • By Tumor Site
    • Brain
    • Spine
    • Eyes
    • Kidneys
    • Adrenal Glands
    • Pancreas
    • Liver
    • Lungs
    • Inner Ears
    • Reproductive Tract
  • By Diagnosis
    • MRI Scan
    • CT Scan
    • Others
  • By End User
    • Hospitals
    • Clinics
    • Diagnostic Centers
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Burzynski Research Institute, Inc.
  • Cellectar Biosciences, Inc.
  • Novartis AG
  • Bedford Laboratories
  • Direct Therapeutics, Inc.
  • Merck KGaA
  • Advantagene, Inc,
  • Eli Lilly and Company
  • DNAtrix, Inc.
  • Astellas US Holding, Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: VON HIPPEL-LINDAU MARKET, BY TUMOR SITE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Tumor Site

    • 4.2. Brain

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Spine

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Eyes

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Kidneys

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Adrenal Glands

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Pancreas

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Liver

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

    • 4.9. Lungs

      • 4.9.1. Key Market Trends, Growth Factors and Opportunities

      • 4.9.2. Market Size and Forecast, By Region

      • 4.9.3. Market Share Analysis, By Country

    • 4.10. Inner Ears

      • 4.10.1. Key Market Trends, Growth Factors and Opportunities

      • 4.10.2. Market Size and Forecast, By Region

      • 4.10.3. Market Share Analysis, By Country

    • 4.11. Reproductive Tract

      • 4.11.1. Key Market Trends, Growth Factors and Opportunities

      • 4.11.2. Market Size and Forecast, By Region

      • 4.11.3. Market Share Analysis, By Country

  • CHAPTER 5: VON HIPPEL-LINDAU MARKET, BY DIAGNOSIS

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Diagnosis

    • 5.2. MRI Scan

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. CT Scan

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: VON HIPPEL-LINDAU MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Clinics

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Diagnostic Centers

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Others

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: VON HIPPEL-LINDAU MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Tumor Site

      • 7.2.3. Market Size and Forecast, By Diagnosis

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Von Hippel-lindau Market

        • 7.2.6.1. Market Size and Forecast, By Tumor Site
        • 7.2.6.2. Market Size and Forecast, By Diagnosis
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Von Hippel-lindau Market

        • 7.2.7.1. Market Size and Forecast, By Tumor Site
        • 7.2.7.2. Market Size and Forecast, By Diagnosis
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Von Hippel-lindau Market

        • 7.2.8.1. Market Size and Forecast, By Tumor Site
        • 7.2.8.2. Market Size and Forecast, By Diagnosis
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Tumor Site

      • 7.3.3. Market Size and Forecast, By Diagnosis

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Von Hippel-lindau Market

        • 7.3.6.1. Market Size and Forecast, By Tumor Site
        • 7.3.6.2. Market Size and Forecast, By Diagnosis
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Von Hippel-lindau Market

        • 7.3.7.1. Market Size and Forecast, By Tumor Site
        • 7.3.7.2. Market Size and Forecast, By Diagnosis
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Von Hippel-lindau Market

        • 7.3.8.1. Market Size and Forecast, By Tumor Site
        • 7.3.8.2. Market Size and Forecast, By Diagnosis
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Von Hippel-lindau Market

        • 7.3.9.1. Market Size and Forecast, By Tumor Site
        • 7.3.9.2. Market Size and Forecast, By Diagnosis
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Von Hippel-lindau Market

        • 7.3.10.1. Market Size and Forecast, By Tumor Site
        • 7.3.10.2. Market Size and Forecast, By Diagnosis
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Von Hippel-lindau Market

        • 7.3.11.1. Market Size and Forecast, By Tumor Site
        • 7.3.11.2. Market Size and Forecast, By Diagnosis
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Von Hippel-lindau Market

        • 7.3.12.1. Market Size and Forecast, By Tumor Site
        • 7.3.12.2. Market Size and Forecast, By Diagnosis
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Tumor Site

      • 7.4.3. Market Size and Forecast, By Diagnosis

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Von Hippel-lindau Market

        • 7.4.6.1. Market Size and Forecast, By Tumor Site
        • 7.4.6.2. Market Size and Forecast, By Diagnosis
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Von Hippel-lindau Market

        • 7.4.7.1. Market Size and Forecast, By Tumor Site
        • 7.4.7.2. Market Size and Forecast, By Diagnosis
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Von Hippel-lindau Market

        • 7.4.8.1. Market Size and Forecast, By Tumor Site
        • 7.4.8.2. Market Size and Forecast, By Diagnosis
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Von Hippel-lindau Market

        • 7.4.9.1. Market Size and Forecast, By Tumor Site
        • 7.4.9.2. Market Size and Forecast, By Diagnosis
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Von Hippel-lindau Market

        • 7.4.10.1. Market Size and Forecast, By Tumor Site
        • 7.4.10.2. Market Size and Forecast, By Diagnosis
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Von Hippel-lindau Market

        • 7.4.11.1. Market Size and Forecast, By Tumor Site
        • 7.4.11.2. Market Size and Forecast, By Diagnosis
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Von Hippel-lindau Market

        • 7.4.12.1. Market Size and Forecast, By Tumor Site
        • 7.4.12.2. Market Size and Forecast, By Diagnosis
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Von Hippel-lindau Market

        • 7.4.13.1. Market Size and Forecast, By Tumor Site
        • 7.4.13.2. Market Size and Forecast, By Diagnosis
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Von Hippel-lindau Market

        • 7.4.14.1. Market Size and Forecast, By Tumor Site
        • 7.4.14.2. Market Size and Forecast, By Diagnosis
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Tumor Site

      • 7.5.3. Market Size and Forecast, By Diagnosis

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Von Hippel-lindau Market

        • 7.5.6.1. Market Size and Forecast, By Tumor Site
        • 7.5.6.2. Market Size and Forecast, By Diagnosis
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Von Hippel-lindau Market

        • 7.5.7.1. Market Size and Forecast, By Tumor Site
        • 7.5.7.2. Market Size and Forecast, By Diagnosis
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Von Hippel-lindau Market

        • 7.5.8.1. Market Size and Forecast, By Tumor Site
        • 7.5.8.2. Market Size and Forecast, By Diagnosis
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Von Hippel-lindau Market

        • 7.5.9.1. Market Size and Forecast, By Tumor Site
        • 7.5.9.2. Market Size and Forecast, By Diagnosis
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Von Hippel-lindau Market

        • 7.5.10.1. Market Size and Forecast, By Tumor Site
        • 7.5.10.2. Market Size and Forecast, By Diagnosis
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Von Hippel-lindau Market

        • 7.5.11.1. Market Size and Forecast, By Tumor Site
        • 7.5.11.2. Market Size and Forecast, By Diagnosis
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Eli Lilly And Company

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Bedford Laboratories

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. DNAtrix, Inc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Astellas US Holding, Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Advantagene, Inc,

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Burzynski Research Institute, Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Cellectar Biosciences, Inc.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Direct Therapeutics, Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Merck KGaA

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Novartis AG

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL VON HIPPEL-LINDAU MARKET, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL VON HIPPEL-LINDAU MARKET FOR BRAIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL VON HIPPEL-LINDAU MARKET FOR SPINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL VON HIPPEL-LINDAU MARKET FOR EYES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL VON HIPPEL-LINDAU MARKET FOR KIDNEYS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL VON HIPPEL-LINDAU MARKET FOR ADRENAL GLANDS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL VON HIPPEL-LINDAU MARKET FOR PANCREAS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL VON HIPPEL-LINDAU MARKET FOR LIVER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL VON HIPPEL-LINDAU MARKET FOR LUNGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL VON HIPPEL-LINDAU MARKET FOR INNER EARS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL VON HIPPEL-LINDAU MARKET FOR REPRODUCTIVE TRACT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL VON HIPPEL-LINDAU MARKET, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL VON HIPPEL-LINDAU MARKET FOR MRI SCAN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL VON HIPPEL-LINDAU MARKET FOR CT SCAN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL VON HIPPEL-LINDAU MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL VON HIPPEL-LINDAU MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL VON HIPPEL-LINDAU MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL VON HIPPEL-LINDAU MARKET FOR CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. GLOBAL VON HIPPEL-LINDAU MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. GLOBAL VON HIPPEL-LINDAU MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. GLOBAL VON HIPPEL-LINDAU MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. NORTH AMERICA VON HIPPEL-LINDAU, BY REGION, 2025-2033 ($MILLION)
  • TABLE 23. NORTH AMERICA VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 24. NORTH AMERICA VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 25. NORTH AMERICA VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. U.S. VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 27. U.S. VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 28. U.S. VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. CANADA VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 30. CANADA VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 31. CANADA VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. MEXICO VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 33. MEXICO VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 34. MEXICO VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 35. EUROPE VON HIPPEL-LINDAU, BY REGION, 2025-2033 ($MILLION)
  • TABLE 36. EUROPE VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 37. EUROPE VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 38. EUROPE VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 39. FRANCE VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 40. FRANCE VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 41. FRANCE VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 42. GERMANY VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 43. GERMANY VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 44. GERMANY VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. ITALY VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 46. ITALY VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 47. ITALY VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 48. SPAIN VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 49. SPAIN VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 50. SPAIN VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. UK VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 52. UK VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 53. UK VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 54. RUSSIA VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 55. RUSSIA VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 56. RUSSIA VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. REST OF EUROPE VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 58. REST OF EUROPE VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 59. REST OF EUROPE VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 60. ASIA-PACIFIC VON HIPPEL-LINDAU, BY REGION, 2025-2033 ($MILLION)
  • TABLE 61. ASIA-PACIFIC VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 62. ASIA-PACIFIC VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 63. ASIA-PACIFIC VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. CHINA VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 65. CHINA VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 66. CHINA VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. JAPAN VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 68. JAPAN VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 69. JAPAN VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. INDIA VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 71. INDIA VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 72. INDIA VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 73. SOUTH KOREA VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 74. SOUTH KOREA VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 75. SOUTH KOREA VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 76. AUSTRALIA VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 77. AUSTRALIA VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 78. AUSTRALIA VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 79. THAILAND VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 80. THAILAND VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 81. THAILAND VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 82. MALAYSIA VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 83. MALAYSIA VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 84. MALAYSIA VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 85. INDONESIA VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 86. INDONESIA VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 87. INDONESIA VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 88. REST OF ASIA PACIFIC VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 89. REST OF ASIA PACIFIC VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 90. REST OF ASIA PACIFIC VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 91. LAMEA VON HIPPEL-LINDAU, BY REGION, 2025-2033 ($MILLION)
  • TABLE 92. LAMEA VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 93. LAMEA VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 94. LAMEA VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 95. BRAZIL VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 96. BRAZIL VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 97. BRAZIL VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 98. SOUTH AFRICA VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 99. SOUTH AFRICA VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 100. SOUTH AFRICA VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 101. SAUDI ARABIA VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 102. SAUDI ARABIA VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 103. SAUDI ARABIA VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 104. UAE VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 105. UAE VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 106. UAE VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 107. ARGENTINA VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 108. ARGENTINA VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 109. ARGENTINA VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 110. REST OF LAMEA VON HIPPEL-LINDAU, BY TUMOR SITE, 2025-2033 ($MILLION)
  • TABLE 111. REST OF LAMEA VON HIPPEL-LINDAU, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 112. REST OF LAMEA VON HIPPEL-LINDAU, BY END USER, 2025-2033 ($MILLION)
  • TABLE 113. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 114. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 115. ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 116. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 117. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. BEDFORD LABORATORIES: KEY EXECUTIVES
  • TABLE 119. BEDFORD LABORATORIES: COMPANY SNAPSHOT
  • TABLE 120. BEDFORD LABORATORIES: OPERATING SEGMENTS
  • TABLE 121. BEDFORD LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 122. BEDFORD LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 123. DNATRIX, INC.: KEY EXECUTIVES
  • TABLE 124. DNATRIX, INC.: COMPANY SNAPSHOT
  • TABLE 125. DNATRIX, INC.: OPERATING SEGMENTS
  • TABLE 126. DNATRIX, INC.: PRODUCT PORTFOLIO
  • TABLE 127. DNATRIX, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128. ASTELLAS US HOLDING, INC.: KEY EXECUTIVES
  • TABLE 129. ASTELLAS US HOLDING, INC.: COMPANY SNAPSHOT
  • TABLE 130. ASTELLAS US HOLDING, INC.: OPERATING SEGMENTS
  • TABLE 131. ASTELLAS US HOLDING, INC.: PRODUCT PORTFOLIO
  • TABLE 132. ASTELLAS US HOLDING, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 133. ADVANTAGENE, INC,: KEY EXECUTIVES
  • TABLE 134. ADVANTAGENE, INC,: COMPANY SNAPSHOT
  • TABLE 135. ADVANTAGENE, INC,: OPERATING SEGMENTS
  • TABLE 136. ADVANTAGENE, INC,: PRODUCT PORTFOLIO
  • TABLE 137. ADVANTAGENE, INC,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 138. BURZYNSKI RESEARCH INSTITUTE, INC.: KEY EXECUTIVES
  • TABLE 139. BURZYNSKI RESEARCH INSTITUTE, INC.: COMPANY SNAPSHOT
  • TABLE 140. BURZYNSKI RESEARCH INSTITUTE, INC.: OPERATING SEGMENTS
  • TABLE 141. BURZYNSKI RESEARCH INSTITUTE, INC.: PRODUCT PORTFOLIO
  • TABLE 142. BURZYNSKI RESEARCH INSTITUTE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. CELLECTAR BIOSCIENCES, INC.: KEY EXECUTIVES
  • TABLE 144. CELLECTAR BIOSCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 145. CELLECTAR BIOSCIENCES, INC.: OPERATING SEGMENTS
  • TABLE 146. CELLECTAR BIOSCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 147. CELLECTAR BIOSCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. DIRECT THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 149. DIRECT THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 150. DIRECT THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 151. DIRECT THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 152. DIRECT THERAPEUTICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153. MERCK KGAA: KEY EXECUTIVES
  • TABLE 154. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 155. MERCK KGAA: OPERATING SEGMENTS
  • TABLE 156. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 157. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 158. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 159. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 160. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 161. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 162. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL VON HIPPEL-LINDAU MARKET SEGMENTATION
  • FIGURE 2. GLOBAL VON HIPPEL-LINDAU MARKET
  • FIGURE 3. SEGMENTATION VON HIPPEL-LINDAU MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN VON HIPPEL-LINDAU MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALVON HIPPEL-LINDAU MARKET
  • FIGURE 11. VON HIPPEL-LINDAU MARKET SEGMENTATION, BY BY TUMOR SITE
  • FIGURE 12. VON HIPPEL-LINDAU MARKET FOR BRAIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. VON HIPPEL-LINDAU MARKET FOR SPINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. VON HIPPEL-LINDAU MARKET FOR EYES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. VON HIPPEL-LINDAU MARKET FOR KIDNEYS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. VON HIPPEL-LINDAU MARKET FOR ADRENAL GLANDS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. VON HIPPEL-LINDAU MARKET FOR PANCREAS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. VON HIPPEL-LINDAU MARKET FOR LIVER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. VON HIPPEL-LINDAU MARKET FOR LUNGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. VON HIPPEL-LINDAU MARKET FOR INNER EARS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. VON HIPPEL-LINDAU MARKET FOR REPRODUCTIVE TRACT, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. VON HIPPEL-LINDAU MARKET SEGMENTATION, BY BY DIAGNOSIS
  • FIGURE 23. VON HIPPEL-LINDAU MARKET FOR MRI SCAN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. VON HIPPEL-LINDAU MARKET FOR CT SCAN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. VON HIPPEL-LINDAU MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. VON HIPPEL-LINDAU MARKET SEGMENTATION, BY BY END USER
  • FIGURE 27. VON HIPPEL-LINDAU MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 28. VON HIPPEL-LINDAU MARKET FOR CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 29. VON HIPPEL-LINDAU MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 30. VON HIPPEL-LINDAU MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 31. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 32. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 33. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 34. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 35. COMPETITIVE DASHBOARD
  • FIGURE 36. COMPETITIVE HEATMAP: VON HIPPEL-LINDAU MARKET
  • FIGURE 37. TOP PLAYER POSITIONING, 2024
  • FIGURE 38. ELI LILLY AND COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. BEDFORD LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. BEDFORD LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. BEDFORD LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. DNATRIX, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. DNATRIX, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. DNATRIX, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. ASTELLAS US HOLDING, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. ASTELLAS US HOLDING, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. ASTELLAS US HOLDING, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. ADVANTAGENE, INC,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. ADVANTAGENE, INC,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. ADVANTAGENE, INC,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. BURZYNSKI RESEARCH INSTITUTE, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. BURZYNSKI RESEARCH INSTITUTE, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. BURZYNSKI RESEARCH INSTITUTE, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. CELLECTAR BIOSCIENCES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. CELLECTAR BIOSCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. CELLECTAR BIOSCIENCES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. DIRECT THERAPEUTICS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. DIRECT THERAPEUTICS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. DIRECT THERAPEUTICS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 62. MERCK KGAA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 63. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 64. MERCK KGAA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 65. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 66. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 67. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Von Hippel-Lindau Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved